Home › Asthma › NCT07426458

Ventilation and Perfusion in Asthmatics

Ventilation and Perfusion in Individuals With Asthma

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

* Physician diagnosis of asthma
* Baseline Forced Expiratory Volume in 1 Second (FEV1) \< 80% of predicted, with reversibility (10%) on post-bronchodilator spirometry
* Adults, 18-75 years of age
* Long-term inhaled controller medication consisting of or including an Inhaled corticosteroids (ICS) at a steady dose for at least 3 months before enrollment

Exclusion Criteria:

* Current cigarette smoking or a past history of \>10 pack-year smoking
* Current nicotine vaping
* Pregnant and breast-feeding women
* Respiratory infection within 4 weeks of proposed study date
* Forced Expiratory Volume in 1 Second (FEV1) \< 50%
* Inhaled corticosteroids (ICS)/fast-acting beta agonist (FABA) intolerance
* Use of beta-blockers
* Use of systemic glucocorticosteroids or oral methyl-xanthines within 30 days of planned study visit.

About the study

Assess regional changes to perfusion and ventilation from inhaled corticosteroid (ICS) and Fast-acting beta-antagonist (FABA) among adult asthmatics using radiographically derived estimates of regional ventilation (V-distribution), ventilation defect percentage (VDP), and ventilation heterogeneity (VH).

What is being tested

• Albuterol Sulfate (drug)
• Albuterol-Budesonide (drug)

Sponsor: University of Miami · Participants: 40 · Started: Apr 27, 2026

Contact the study team

• Maria McCoy · Phone: 305-243-2568
• Sonia Dipti Meena Velmurugan, MS · Phone: 305-243-2568

Official record on ClinicalTrials.gov — NCT07426458

Locations in the U.S.

Conditions

• Asthma

From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.